Clinical trials coverage from Pharma Journal: trial design, regulatory milestones, patient recruitment and phase readouts across the UK and global pipeline. The studies shaping tomorrow's medicines, from first-in-human work to pivotal results and the approvals that follow.
The CHMP has issued a positive opinion on Foundayo (orforglipron) for obesity and type 2 diabetes. We examine the ATTAIN-1 data and regulatory next steps.
By Dr. Eleanor Vance, Regulatory Affairs Editor
In the SOLARIS trial, Weltruza lowered schizophrenia symptom scores by 9.75 to 11.27 points more than placebo at 8 weeks, with more weight gain and no peer-reviewed report yet. It is not approved in the UK or EU.
By Pharma Journal Editorial Desk, Editorial Desk
The FDA approved atezolizumab for stage III dMMR colon cancer on 8 October 2026. Here is what the ATOMIC trial numbers actually show — and what remains unknown.
By Dr. Eleanor Vance, Regulatory Affairs Editor
The UK's new clinical trials regulations enter force 28 April 2026. Here is what the notification scheme, combined review, and results disclosure obligations mean for sponsors and CROs.
By Dr. Eleanor Vance, Regulatory Affairs Editor
The primary endpoint data from the EVOKE and EVOKE Plus trials, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in late 2024 and subsequently reported in Nature Medicine (2025), show that semaglutide (Novo Nordisk; Ozempic at 1mg subcutaneous weekly)…
By Tom Okafor, Clinical Trials Correspondent
A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.
By Tom Okafor, Clinical Trials Correspondent
The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, signed into law in April 2025 and entering into force on 28 April 2026, represent the most substantial revision to the UK clinical trial regulatory framework since the original 2004 Regulations…
By Dr. Eleanor Vance, Regulatory Affairs Editor
DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?
By Tom Okafor, Clinical Trials Correspondent
The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Microbiome on chip systems could revolutionise drug discovery by providing human-relevant gut testing, potentially reducing the 90% clinical trial failure rate.
By Tom Okafor, Clinical Trials Correspondent
The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c
By Tom Okafor, Clinical Trials Correspondent
AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.
By Tom Okafor, Clinical Trials Correspondent
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy